Vmbook Online ordering

Novavax Inc

Novavax, Inc. is a public biotechnology company based in the United States that specializes in the development of vaccines for infectious diseases. The company is headquartered in Gaithersburg, Maryland.

Novavax is listed on the Nasdaq stock exchange under the ticker symbol “NVAX”. As of February 2023, the company has a market capitalization of around 3.5 billion dollars.

The company's main focus is on the development of vaccines for respiratory diseases, including influenza and COVID-19. Its leading vaccine candidate for COVID-19, NVX-CoV2373, is a protein-based vaccine that has shown promising results in clinical trials. The company has also developed a seasonal influenza vaccine, NanoFlu, which is currently in Phase 3 clinical trials.

Novavax was founded in 1994 and has been listed on the Nasdaq stock exchange since 2000. The company has received significant funding from both private and public sources, including grants from the US government's Biomedical Advanced Research and Development Authority (BARDA) and the Coalition for Epidemic Preparedness Innovations (CEPI).

It's worth noting that the stock price of Novavax, like any other stock, is subject to various market and company-specific factors, and it's important to conduct your own research or consult with a financial advisor before making any investment decisions.